• The Rare Disease market is expanding. Liberi Group identifies a strong demand for high quality rare disease projects from pharma companies and investors in the coming decade.
  • Rare Disease business development is a challenging specialist sector within life science business development
  • Sourcing of high quality projects is a major challenge – large proportion of Rare Diseases project remain under the radar screen
  • Current travel restrictions and cultural barriers hamper Rare Disease business development both on sides of supply and demand
  • At Liberi Group we support pharma, biotech and investors with the tools to scout Rare Disease projects and with contacts and know-how for Rare Disease business development in unfamiliar markets.

Rare Diseases

Current physical and cultural barriers slow-down Rare Disease business development

>3000 rare disease drug development programs

  • The Liberi Rare Disease Drug Development database has been constructed over the last 10 years from data collected from meeting companies with Rare Disease programs, as well as data collected from publically available data from, health authorities, regulatory bodies, trade organisations, chambers of commerce, rare disease organisations, clinical trial information, patents and scientific articles.
  • The Liberi Rare Disease Drug Development database covers almost all therapeutic areas and all therapeutic classes, and it contains projects from all major geographic regions
  • The Liberi Rare Disease Drug Development database contains project details from >3,000 therapeutic candidates , including therapeutic characteristics, lead indication and latest reported development stage, as well as backgroud information and contact details of the developer
  • The Liberi Rare Disease Drug Development database allows mining based on compound name, compound description, disease, disease category, drug-class, genetic predisposition, development stage

The rare disease business development market is highly specialized global market where supply struggles to find demand due to current restrictions and cultural barriers

  • Liberi Group has direct access to key decision makers in all major pharma companies with an interest in Rare Disease projects